Carbamazepine-induced systemic lupus erythematosus: A case-based review

Area of Science:

• Rheumatology
• Clinical Immunology
• Pharmacology

Background:

• Drug-induced systemic lupus erythematosus (DILE) is a significant adverse effect of various medications.
• Carbamzepine (CBZ) is an antiepileptic drug with known potential to induce DILE.
• Understanding the specific characteristics of CBZ-DILE is crucial for accurate diagnosis and management.

Purpose of the Study:

• To define the clinical and serological characteristics of carbamazepine-induced drug-induced lupus erythematosus (CBZ-DILE).
• To compare CBZ-DILE with systemic lupus erythematosus (SLE) triggered by other drugs (DILE).

Main Methods:

• Case presentation of a patient with CBZ-DILE.
• Literature review of published CBZ-DILE cases.
• Comparative analysis of clinical and serological data.

Main Results:

• CBZ-DILE exhibits variable latency periods, often years, unrelated to CBZ dosage.
• Common manifestations include arthralgia/arthritis, mucocutaneous issues, constitutional symptoms, and serositis; renal involvement is rare.
• Antihistone antibodies are less frequent, while anti-dsDNA antibodies are more common in CBZ-DILE compared to classic DILE.

Conclusions:

• CBZ-DILE presents distinct clinical and laboratory features differentiating it from classic DILE and idiopathic SLE.
• Discontinuation of CBZ is effective in resolving symptoms.
• Continued monitoring of antinuclear antibodies (ANA) is warranted as they may remain positive post-withdrawal.